AU2002334126B2 - Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma - Google Patents

Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma Download PDF

Info

Publication number
AU2002334126B2
AU2002334126B2 AU2002334126A AU2002334126A AU2002334126B2 AU 2002334126 B2 AU2002334126 B2 AU 2002334126B2 AU 2002334126 A AU2002334126 A AU 2002334126A AU 2002334126 A AU2002334126 A AU 2002334126A AU 2002334126 B2 AU2002334126 B2 AU 2002334126B2
Authority
AU
Australia
Prior art keywords
salmeterol
asthma
fluticasone propionate
treatment
xinafoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002334126A
Other languages
English (en)
Other versions
AU2002334126A1 (en
Inventor
Brian Charles Gavin
Jennifer Anne Sykes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2002334126A1 publication Critical patent/AU2002334126A1/en
Application granted granted Critical
Publication of AU2002334126B2 publication Critical patent/AU2002334126B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002334126A 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma Ceased AU2002334126B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0124523.2 2001-10-12
GBGB0124523.2A GB0124523D0 (en) 2001-10-12 2001-10-12 Pharmaceutical combination
PCT/GB2002/004602 WO2003033000A1 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma

Publications (2)

Publication Number Publication Date
AU2002334126A1 AU2002334126A1 (en) 2003-07-03
AU2002334126B2 true AU2002334126B2 (en) 2005-12-15

Family

ID=9923709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002334126A Ceased AU2002334126B2 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma

Country Status (7)

Country Link
US (1) US20050042171A1 (enExample)
EP (1) EP1434587A1 (enExample)
JP (1) JP2005508963A (enExample)
AU (1) AU2002334126B2 (enExample)
CA (1) CA2463435A1 (enExample)
GB (1) GB0124523D0 (enExample)
WO (1) WO2003033000A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
WO2007096782A2 (en) * 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
TR201000685A2 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
BR112013012994A2 (pt) 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
EP2991626A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
PL3054920T3 (pl) * 2013-10-07 2021-07-05 Teva Branded Pharmaceutical Products R&D, Inc. Inhalator suchego proszku
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB2235627B (en) * 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination

Also Published As

Publication number Publication date
CA2463435A1 (en) 2003-04-24
GB0124523D0 (en) 2001-12-05
WO2003033000A1 (en) 2003-04-24
US20050042171A1 (en) 2005-02-24
EP1434587A1 (en) 2004-07-07
JP2005508963A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
US20050042171A1 (en) Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
WO2001078745A1 (en) Medical combinations comprising formoterol and fluticasone proprionate
US20030119859A1 (en) Medical combinations comprising tiotropium and rofleponide
AU2002334126A1 (en) Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
EP1274437A1 (en) Medical combinations comprising tiotropium and fluticasone proprionate
US20030109510A1 (en) Medical combinations comprising formoterol and budesonide
EP1274440A1 (en) Medical combinations comprising tiotropium and mometasone
US20050042174A1 (en) Combined doses
US20040009963A1 (en) Use of salmeterol and fluticasone propionate combination
US20050053553A1 (en) Combined doses of formoterol and fluticasone
US20030125313A1 (en) Medical combination comprising salmeterol and budesonide
CA2529127A1 (en) Combined doses of tiotropium and fluticasone
US20030114537A1 (en) Medical combinations comprising mometasone and salmeterol
WO2001078744A1 (en) Medical combinations comprising formoterol and mometasone
EP1274436A1 (en) Medical compositions comprising (r,r)-formoterol und rofleponide
US20030096874A1 (en) Respiratory compositions
US20040019025A1 (en) Medical compositions comprising (r,r)-formoterol and rofleponide
WO2002019995A2 (en) Pharmaceutical combination containing salmeterol and fluticasone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired